The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

For a long time, the combination of an inhaled corticosteroid (ICS) and a long-acting β-agonist (LABA) inhaler agent was considered the mainstay of treating chronic obstructive pulmonary disease (COPD) patients with severe airflow obstruction and frequent exacerbations. More recently, the role of ICS in the treatment paradigm of patients with severe COPD and frequent exacerbations has been challenged. This is mainly driven by: 1) the growing evidence of an increased risk of pneumonia associated with ICS; 2) the introduction of combined dual long-acting bronchodilator inhalation therapy with a long-acting muscarinic antagonist (LAMA) and a LABA therapy as a plausible and likely superior treatment alternative; and 3) the recognition that probably not all COPD exacerbation phenotypes stand to equally benefit from ICS therapy, e.g. patients with high blood eosinophil counts probably stand to benefit more from ICS therapy than those with low eosinophil counts. The Informing the Pathway of COPD Treatment (IMPACT) study aimed to address the question of whether ICS in addition to dual therapy with LAMA/LABA can reduce moderate and severe acute exacerbations of COPD (AECOPD) compared with LAMA/LABA therapy alon
Original languageEnglish
Pages (from-to)333-335
Number of pages3
JournalBreathe
Volume14
Issue number4
DOIs
Publication statusPublished - 1 Dec 2018
Externally publishedYes

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Muscarinic Antagonists
Therapeutics
Eosinophils
Disease Progression
Respiratory Therapy
Bronchodilator Agents
Pneumonia
Phenotype

Cite this

@article{1a5911dbfe0e4cb1bdfd5a21249763f8,
title = "The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD",
abstract = "For a long time, the combination of an inhaled corticosteroid (ICS) and a long-acting β-agonist (LABA) inhaler agent was considered the mainstay of treating chronic obstructive pulmonary disease (COPD) patients with severe airflow obstruction and frequent exacerbations. More recently, the role of ICS in the treatment paradigm of patients with severe COPD and frequent exacerbations has been challenged. This is mainly driven by: 1) the growing evidence of an increased risk of pneumonia associated with ICS; 2) the introduction of combined dual long-acting bronchodilator inhalation therapy with a long-acting muscarinic antagonist (LAMA) and a LABA therapy as a plausible and likely superior treatment alternative; and 3) the recognition that probably not all COPD exacerbation phenotypes stand to equally benefit from ICS therapy, e.g. patients with high blood eosinophil counts probably stand to benefit more from ICS therapy than those with low eosinophil counts. The Informing the Pathway of COPD Treatment (IMPACT) study aimed to address the question of whether ICS in addition to dual therapy with LAMA/LABA can reduce moderate and severe acute exacerbations of COPD (AECOPD) compared with LAMA/LABA therapy alon",
author = "Dobler, {Claudia C.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1183/20734735.026418",
language = "English",
volume = "14",
pages = "333--335",
journal = "Breathe",
issn = "1810-6838",
publisher = "EUROPEAN RESPIRATORY SOCIETY-ERS",
number = "4",

}

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD. / Dobler, Claudia C.

In: Breathe, Vol. 14, No. 4, 01.12.2018, p. 333-335.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD

AU - Dobler, Claudia C.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - For a long time, the combination of an inhaled corticosteroid (ICS) and a long-acting β-agonist (LABA) inhaler agent was considered the mainstay of treating chronic obstructive pulmonary disease (COPD) patients with severe airflow obstruction and frequent exacerbations. More recently, the role of ICS in the treatment paradigm of patients with severe COPD and frequent exacerbations has been challenged. This is mainly driven by: 1) the growing evidence of an increased risk of pneumonia associated with ICS; 2) the introduction of combined dual long-acting bronchodilator inhalation therapy with a long-acting muscarinic antagonist (LAMA) and a LABA therapy as a plausible and likely superior treatment alternative; and 3) the recognition that probably not all COPD exacerbation phenotypes stand to equally benefit from ICS therapy, e.g. patients with high blood eosinophil counts probably stand to benefit more from ICS therapy than those with low eosinophil counts. The Informing the Pathway of COPD Treatment (IMPACT) study aimed to address the question of whether ICS in addition to dual therapy with LAMA/LABA can reduce moderate and severe acute exacerbations of COPD (AECOPD) compared with LAMA/LABA therapy alon

AB - For a long time, the combination of an inhaled corticosteroid (ICS) and a long-acting β-agonist (LABA) inhaler agent was considered the mainstay of treating chronic obstructive pulmonary disease (COPD) patients with severe airflow obstruction and frequent exacerbations. More recently, the role of ICS in the treatment paradigm of patients with severe COPD and frequent exacerbations has been challenged. This is mainly driven by: 1) the growing evidence of an increased risk of pneumonia associated with ICS; 2) the introduction of combined dual long-acting bronchodilator inhalation therapy with a long-acting muscarinic antagonist (LAMA) and a LABA therapy as a plausible and likely superior treatment alternative; and 3) the recognition that probably not all COPD exacerbation phenotypes stand to equally benefit from ICS therapy, e.g. patients with high blood eosinophil counts probably stand to benefit more from ICS therapy than those with low eosinophil counts. The Informing the Pathway of COPD Treatment (IMPACT) study aimed to address the question of whether ICS in addition to dual therapy with LAMA/LABA can reduce moderate and severe acute exacerbations of COPD (AECOPD) compared with LAMA/LABA therapy alon

UR - http://www.scopus.com/inward/record.url?scp=85059272564&partnerID=8YFLogxK

U2 - 10.1183/20734735.026418

DO - 10.1183/20734735.026418

M3 - Article

VL - 14

SP - 333

EP - 335

JO - Breathe

JF - Breathe

SN - 1810-6838

IS - 4

ER -